Technical analysis of Sagimet Biosciences Inc. (SGMT): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Price Performance
| 1 month | -1.13% |
| 3 months | +56.59% |
| Year-to-date | +76.69% |
| 1 year | +70.08% |
| 3 years | -9.52% |
52-Week Range
| 52-week High | $11.45 |
| 52-week Low | $4.50 |
| Avg Volume (90d) | 1.1M |
Technical Indicators
| SMA 50 | $9.11 |
| SMA 200 | $6.95 |
| Beta | 3.21 |
| 30-day Volatility (annualised) | 55.3% |
| Price vs SMA 50 | +14.8% |
| Price vs SMA 200 | +50.4% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $8.52 | |
| 2025-11 | $7.22 | -15.3% |
| 2025-12 | $5.92 | -18.0% |
| 2026-01 | $5.67 | -4.2% |
| 2026-02 | $5.71 | +0.7% |
| 2026-03 | $5.23 | -8.4% |
| 2026-04 | $8.03 | +53.5% |
| 2026-05 | $7.29 | -9.2% |
| 2026-06 | $7.73 | +6.0% |
| 2026-07 | $7.11 | -8.0% |
| 2026-08 | $10.26 | +44.3% |
| 2026-09 | $10.46 | +1.9% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $10.46 |
| Market Cap | $341M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.17 |
| EV / EBITDA | -3.87 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 45.02 |